Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357992 · ClinicalTrials.gov registry record · NA
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 122
- Enrollment target
NCT02357992: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT02357992 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 122 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02357992, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC. Specifically, researchers want to learn if standard SRT has as good of an outcome at 3 years after the procedure. The safety of the study treatment will also be analyzed.
Interventions
- RADIATION Stereotactic Body Radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-04-05 |
| Est. Completion | 2021-09-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02357992
The ClinicalTrials.gov registry entry for NCT02357992 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Body Radiotherapy (SABR) is the first listed.
NCT02357992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02357992 about?
NCT02357992 is a clinical study titled "Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy". The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC. Specifically, researchers want to learn if standard SRT has as good of an outcome at 3 years after the procedure. The safety of the study treatment...
What is the current status of trial NCT02357992?
This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2010-04-05. Estimated completion is 2021-09-17.
What interventions are being tested in trial NCT02357992?
The interventions under investigation include: Stereotactic Body Radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT02357992?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.